This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MGT Capital Investments, Inc. Establishes Special Committee To Launch Investigation

LONDON, July 11, 2011 /PRNewswire/ -- MGT Capital Investments, Inc. ("MGT" or "the Company") (NYSE Amex: MGT) announced today that its Board of Directors has established a special committee to investigate potential misappropriation and/or misdirection of Company funds. MGT's majority-owned subsidiary, Medicsight PLC (London AIM: MDST), has also launched a similar investigation.

While it is too early to determine the outcome of these investigations or the financial impact, if any, to the Company, management believes that no potential wrongdoing occurred post February 7, 2011, when the current MGT board was constituted and the current MGT officers were appointed.  

In the event the investigation results in any finding of wrongdoing, the Company plans to pursue recovery and/or restitution to the fullest extent provided by law.  However, in such an event, there can be no assurance of any recovery, or that any recovery will exceed the costs of collection, the costs of any litigation (including settlements as well as legal fees) relating to this matter, or any other costs associated with this matter, including but not limited to payment of taxes or fines, and the findings of unreported claims on the Company's assets.

SUSPENSION OF MEDICSIGHT CEO AND RESIGNATION OF MEDICSIGHT BOARD MEMBER

On July 8, 2011, the Board of Directors of Medicsight PLC announced that Allan Rowley, Chief Executive Officer of Medicsight, has been suspended from his Executive responsibilities with immediate effect pending the outcome of the investigations.  Robert Ladd, Non-Executive Director of Medicsight and interim CEO of MGT, will assume the role of interim Chief Executive Officer of Medicsight until the investigations are concluded.

Medicsight also announced that Steven Harris, a recently appointed non-executive director, has tendered his resignation from the Board of Medicsight effective immediately.

TEMPORARY SUSPENSION OF TRADING OF MEDICSIGHT STOCK ON THE AIM EXCHANGE IN LONDON

On the advice of its Nominated Advisor, Daniel Stewart & Company, Medicsight has also received a temporary suspension of trading of its ordinary shares on London's AIM Exchange pending clarification of the Company's financial position.  

AMEX LISTING

MGT also reported today that it has been granted a one week extension by the NYSE Amex (the "Exchange") to submit a plan of compliance demonstrating its ability to regain compliance with the Exchange listing standards within an 18 month remediation period.  The Company intends to submit such plan by July 15, 2011.

As reported on June 14, 2011, MGT announced that on June 8, 2011 it received notice from the NYSE Amex (the "Exchange") that it is not in compliance with following Exchange continued listing standards:  Section 1003(a)(i) of the Company Guide, resulting from stockholders' equity on March 31, 2011 of less than $2,000,000 and losses from continuing operations and/or net losses in two of its three most recent fiscal years; Section 1003(a)(ii) of the Company Guide with stockholders' equity of less than $4,000,000 and losses from continuing operations and/or net losses in three of its four most recent fiscal years; and Section 1003(a)(iii) with stockholders' equity of less than $6,000,000 and losses from continuing operations and/or net losses in its five most recent fiscal years.

Mr. Ladd commented, "MGT appreciates the Exchange's accommodation given recent events.  Following the improvements in corporate governance implemented earlier this year, MGT has every intention of enhancing financial performance and taking steps to regain compliance with all applicable Exchange listing requirements."  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,260.78 -24.96 -0.14%
S&P 500 2,129.01 -1.81 -0.08%
NASDAQ 5,093.0560 +2.2620 0.04%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs